Chapter

Human Immunodeficiency Virus type 1 (HIV-1) and Breastfeeding

Volume 743 of the series Advances in Experimental Medicine and Biology pp 173-183

Date:

Antiretroviral Drugs During Breastfeeding for the Prevention of Postnatal Transmission of HIV-1

  • Athena P. KourtisAffiliated withDivision of Reproductive Health, NCCDPHP, Centers for Disease Control and Prevention Email author 
  • , Isabelle de VincenziAffiliated withWorld Health Organization
  • , Denise J. JamiesonAffiliated withDivision of Reproductive Health, NCCDPHP, Centers for Disease Control and Prevention
  • , Marc BulterysAffiliated withDivision of Global HIV/AIDS (DGHA), Center for Global Health, Centers for Disease Control and Prevention (CDC)CDC Global AIDS ProgramUCLA School of Public Health

* Final gross prices may vary according to local VAT.

Get Access

Abstract

The global pediatric human immunodeficiency virus (HIV) type 1 epidemic is fueled to a large extent by postnatal transmission from mother to infant through breastfeeding. As many as 90% of the estimated 430,000 new HIV infections in children less than 15 years of age in 2008 were due to mother-to-child transmission (MTCT) [1]. MTCT can occur in utero, intrapartum, or postpartum through breastfeeding; among children with known timing of infection, as much as 30–40% of MTCT of HIV-1 is attributable to breastfeeding; this proportion may be even higher in settings where effective interventions that decrease in utero and intrapartum transmission are being implemented [2–4].